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Abstract The innate immune system and inflammatory response in the brain have critical impacts on the 
pathogenesis of many neurodegenerative diseases including Alzheimer’s disease (AD). In the central nervous 
system (CNS), the innate immune response is primarily mediated by microglia. However, non-glial cells such as 
neurons could also partake in inflammatory response independently through inflammasome signalling. The NLR 
family pyrin domain-containing 1 (NLRP1) inflammasome in the CNS is primarily expressed by pyramidal 
neurons and oligodendrocytes. NLRP1 is activated in response to amyloid-β (Aβ) aggregates and its 
activation subsequently cleaves caspase-1 into its active subunits. The activated caspase-1 proteolytically 
processes interleukin-1β and interleukin-18 (IL-1β and IL-18) into maturation whilst co-ordinately triggers 
caspase-6 which is responsible for apoptosis and axonal degeneration. In addition, caspase-1 activation also 
induces pyroptosis, an inflammatory form of programmed cell death. Studies in murine AD models indicate that 
the NLRP1 inflammasome is indeed upregulated in AD and neuronal death is observed leading to cognitive 
decline. However, the mechanism of NLRP1 inflammasome activation in AD is particularly elusive, given its 
structural and functional complexities. In this review, we examine the implications of the human NLRP1 
inflammasome and its signalling pathways in driving neuroinflammation in AD. 
 
Keywords: Alzheimer’s disease, Caspase-1, Interleukin-1β, Interleukin-18, Neuroinflammation, NLRP1 
inflammasome 
 
 
 
 
 
 
 
 
 
3 
 
Introduction 
Alzheimer’s disease (AD) is a progressive, irreversible neurodegenerative disease which gradually 
damages patients’ memory and cognitive functions. It is the most common cause of dementia, accounting for 60-
80% of total dementia cases [1]. The clinical symptoms of AD include memory loss, behavioural fluctuations, 
and difficulty in speech, problem-solving and basic cognitive functions - all of which are attributed to the shrinking 
of select regions in the brain caused by widespread neuronal loss. As the brain continues to deteriorate, the 
symptoms worsen and eventually leading to death. At present, there is no available treatment capable of modifying 
or reversing the progression of AD. Current clinical interventions such as cholinesterase inhibitors (e.g. Donzepil, 
Rivastigmine, and Galantamine) for early to moderate stages of AD, and N-methyl-D-aspartate inhibitors (e.g. 
Memantine) for late to severe AD, are limited to symptom management and improvement of quality of life [2]. 
The aetiology of AD has remained elusive ever since the disease was first described. Two well-known 
pathological hallmarks of AD, namely senile plaques (primarily composed of amyloid-β (Aβ) peptides) and 
neurofibrillary tangles (NFTs, primarily composed of tau proteins), have been a major focus in contemporary AD 
research [3]. To cure AD, however, remains challenging as our knowledge in AD pathophysiology has not yet 
translated into the development of drugs that target the root cause of the disease. Several drugs designed to reduce 
Aβ production or aggregation such as rosiglitazone, semagacestat, tarenflurbil, tramiprosate and scyllo-inositol 
have failed in clinical trials either due to ineffectiveness or severe side effects [4]. As reported in 2018, there are 
approximately 17 potentially disease-modifying drugs in Phase III clinical trial which include 14 drugs targeting 
amyloid and one targeting tau [5]. In the wake of the second failure of aducanumab in a recent Phase III clinical 
trial, we are forced to consider novel approaches towards future AD drug development that targets beyond the 
conventional AD pathologies. 
 In recent years, neuroinflammation has received much attention as a potential driver of  
neurodegeneration, and its implications in AD is evident in genetic studies, neuroimaging and biopsies of patients, 
as reviewed in: [6,7]. As inquiries in the roles of neuroinflammation in AD gain traction, a type of multiprotein 
complex known as the inflammasome has garnered much interest for its part in inflammation regulation. 
Inflammasomes serve as platforms for the recruitment and activation of caspase-1, the de facto executioner of a 
diverse downstream inflammatory processes including the maturation of two major pro-inflammatory cytokines 
interleukin-1β (IL-1β) and IL-18 [8]. Several types of inflammasomes have been identified within the central 
nervous system (CNS), of which the best characterized are the absent in melanoma 2 (AIM2), NLR-family pyrin 
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domain-containing 1 (NLRP1), NLR-family pyrin domain-containing 3 (NLRP3) and NLR-family CARD-
containing 4 (NLRC4) inflammasomes [9]. Recently, the NLRP1 inflammasome was shown to co-activate with 
NLRP3 inflammasome in monocytes of AD patients [10]. In AD brains, there is approximately 25- to 30-fold 
increase in neuronal NLRP1 immunopositivity compared to non-AD brains [11]. As such, we propose that the 
NLRP1 inflammasome in neurons play a pivotal role in contributing towards neuroinflammation in AD. In this 
review, we consolidate the latest findings on the structure and mechanisms of regulation and activation of the 
NLRP1 inflammasome. Then, we examine potential roles of neuronal NLRP1 inflammasome and its 
corresponding signalling pathways in contributing towards neurodegeneration in AD. 
 
The innate immune system, inflammation and inflammasomes in the CNS 
The innate immune system acts as a forefront in host defence against infectious pathogens as well as 
non-infectious harmful stimuli. In the periphery, innate immunity is modulated by immune cells such as mast 
cells, dendritic cells, macrophages and neutrophils. [12,13]. These immune cells recognize molecules associated 
with groups of pathogens termed pathogen-associated molecular patterns (PAMPs) or with sterile tissue injuries 
termed danger-associated molecular patterns (DAMPs) [14]. These signals are recognized through germline-
encoded pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), the retinoic acid-inducible gene-
I-like receptors (RIG-I-like receptor or RLRs), C-type lectin receptors (CLRs) and the nucleotide oligomerization 
domain-like receptors (NOD-like receptors or NLRs), as well as a number of DNA-sensing molecules including 
the pyrin and HIN domain-containing (PYHIN) receptors [15,16]. When engaged, these receptors function in 
synergy to promote maturation and secretion of pro-inflammatory cytokines and molecules which results in 
inflammation and pathogen clearance. 
The central nervous system (CNS) is separated from the peripheral circulatory system by the blood-brain 
barrier (BBB), a highly selective semi-permeable membrane barrier which shield the CNS against external injury, 
toxins and pathogens [17]. In addition, the sanctity of the CNS is protected by microglia and astrocytes which 
makes up its primary resident immune cells. The roles of these glial cells in immunity are reviewed in: [18,19]. 
While the primary function of these cells are to maintain homeostasis and to provide support for neuronal 
functions, they are capable of eliciting innate immune responses against infections and stimulate inflammation 
within the CNS, more commonly known as neuroinflammation. Surprisingly, even neurons are shown to be 
capable of participating in such responses through the expression of PRRs and the production of pro-inflammatory 
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cytokines [20,21]. Although inflammation is intended to be protective in nature, dysregulated inflammation can 
instead lead to severe tissue damage and even death. In the CNS, neuroinflammation is widely implicated in 
various neurogenerative diseases including AD, Parkinson’s disease (PD), Huntington’s disease (HD) and 
amyotrophic lateral sclerosis (ALS), as reviewed in: [22]. 
In AD, chronic neuroinflammation is believed to be the possible missing link between neuritic plaques, 
NFTs and neuronal death [6]. One of the cardinal signs of neuroinflammation in AD is in the patients’ cytokine 
profile. The mRNA expression of several major cytokines (interleukins, tumour necrosis factor α converting 
enzyme (TACE), and transforming growth factor β1 (TGFβ1)) are significantly upregulated in the brains of AD 
patients compared to non-demented controls [23]. Moreover, a meta-analysis has indicated elevated levels of pro-
inflammatory cytokines including tumour necrosis factor α  (TNFα), TGFβ1, IL-1β and IL-18 found in the 
peripheral blood of AD patients further substantiates the association between inflammation and AD [24]. 
Interestingly, this spike in cytokine expression is only observed in late stage AD with significant cognitive decline, 
but not in its pre-symptomatic stages, suggesting that neuroinflammation may be a secondary response to external 
factors such as A which rapidly escalates with greater amyloid deposition. Moreover, leaky blood-brain barrier 
typically observed in brains of AD patients further encourages influx of toxic molecules, pathogens, peripheral 
immune cells and pro-inflammatory cytokines which collectively escalates the severity of neuroinflammation 
[25]. 
In recent years, a wealth of literature points toward inflammasomes in the CNS as an important driver of 
AD pathogenesis through caspase-1-mediated neuroinflammatory responses against Aβ [26–29]. Inflammasomes 
are assembled as a cluster of PRR which recruit caspase-1 via an adaptor protein known as apoptosis-associated 
speck-like protein containing a caspase recruitment domain (ASC). Among the PRRs, only NLRs and PYHINs 
are capable of forming inflammasomes [30]. The NLRP3 inflammasome expressed in microglia is the most 
extensively studied of all the inflammasomes and its roles in AD is well-established [29,31,32]. While studies in 
inflammasomes in neurons have been relatively scant, several types namely AIM2, NLRC4 and NLRP1, have 
been identified and may elicit similar neuroinflammatory processes [11,33]. Within neurons, the NLRP1 
inflammasome is particularly relevant in AD. A cohort study has identified four non-synonymous single 
nucleotide polymorphisms (SNPs) in the NLRP1 gene are associated with increased AD susceptibility; rs2137722 
(Arg1322Cys), rs3473379 (Thr995Ile), rs11657747 (Thr878Met), and rs11651595 (Thr246Ser) [34], although 
these data are not confirmed in the latest genome-wide association (GWA) meta-analysis [35]. However, in vivo 
and in vitro exposure of neurons to Aβ in AD murine models have shown to induce Nlrp1-dependent neuronal 
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loss [36]. In the human brain, there is a significant increase in NLRP1 mRNA, but not NLRP3, expressed in the 
cerebellum and cortex of AD brains compared to healthy controls, with 25- to 30- fold increase in NLRP1 
immunopositive staining within the hippocampus. NLRP1, and subsequently caspase-1 activity, also co-
ordinately activate caspase-6 which consequentially leads to neuroinflammation and axonal degeneration [11]. 
All these studies allude to NLRP1’s contribution towards neurodegeneration in AD (Fig. 1). 
 
The NLRP1 inflammasome: Structure and mechanism of activation 
Although NLRP1 was the first inflammasome to be described, its properties remained particularly 
enigmatic as studies were hindered by numerous complications such as the uncertainty of its specific ligands and 
the substantial structural and functional divergence between the human NLRP1 and its murine counterpart [37,38]. 
Although found in a diverse mammalian species, the NLRP1 inflammasome has undergone considerable 
modifications among these species. For example, there are three paralogs which exist in mice for the Nlrp1 gene, 
namely Nlrp1a, Nlrp1b and Nlrp1c, whilst only a single NLRP1 gene exists in humans (Fig. 2) [39]. Moreover, 
alternative splicing has resulted in considerable polymorphism both within and between species. In humans, there 
are seven isoforms of NLRP1 that is known to exist, each with altered protein sequences at the C-terminal region. 
The specific activators for the NLRP1 inflammasome are also varied between the human and rodent orthologues. 
For example, while it is known that mouse Nlrp1b, the species that exhibit the most similarity with that of 
human’s, is reactive towards anthrax lethal factor (LF) due to the presence of an LF cleavage site located at the 
N-terminal region [40], human NLRP1 does not produce a similar response. This poses a challenge in accurately 
modelling human NLRP1 and its related diseases in animal models.  
As a member of the NLR family, the ‘canonical’ full-length human NLRP1 (1473 amino acids; 165.9 kDa) 
contains a central NLR which consists of a nucleotide oligomerization domain (NOD) to facilitate the post-
activation assembly of the inflammasome core and a leucine-rich repeat (LRR) domain which acts as an 
autoinhibitory domain [41]. In common with the NLRP sub-family, a pyrin domain (PYD) is attached to its N-
terminus [42]. Additionally, NLRP1 contains a unique ‘function-to-find’ (FIIND) domain which is flanked by 
LRR and caspase recruitment domain (CARD). The FIIND domain is only shared with another inflammasome-
related protein known as CARD family member 8 (CARD), and bioinformatic analyses revealed that FIIND is 
structurally remarkably similar to a combination of two domains namely ZU5 and UPA [43]. It has therefore been 
suggested that FIIND be renamed ZU5-UPA-like domain (for convention’s sake, we will continue to refer to this 
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domain as FIIND). The post-translational auto-proteolytic cleavage within the FIIND domain is strictly necessary 
for the NLRP1 activation [44]. This cleavage is initiated by deprotonation of Ser1213 located within the FIIND 
domain by a highly-conserved distal His1186 residue. Incidentally, an SNP near His1186 disrupts the cleavage within 
FIIND region and hence prevents NLRP1 activation. As the name suggests, the precise function of this FIIND 
cleavage is yet to be determined, but presumably it is important for complex formation to enable ASC and caspase-
1 interactions [45].  
Unlike other NLRPs including murine Nlrp1, the human NLRP1 simultaneously contains both PYD and 
CARD within its structure. These proteins belong to the death domain (DD) superfamily which are protein-protein 
interaction domains for apoptotic or inflammatory signal transduction [37,46,47]. Although the human NLRP1 
contains two signal transduction domains, surprisingly the PYD of NLRP1 is dispensable whereas the CARD 
appears to be its bona fide effector domain. Crystallization and nuclear magnetic resonance spectroscopy analyses 
revealed structural distinctions between NLRP1’s PYD compared to the PYD of other NLRs [48,49] with the 
most conspicuous difference being the lack of a defined 3 helix, one of the six conserved -helices typical of 
the DD superfamily, which instead is replaced by a flexible loop. This unique structural feature may be sufficient 
to modify the function of NLRP1 PYD. Studies have demonstrated that the proteolytic cleavage of NLRP1 N-
terminus is a general molecular mechanism for its activation [50,51]. In humans, this cleavage occurs at the 
unusually long linker region between PYD and NOD, resulting in a severed PYD. In a study by Chavarría-Smith 
et al., a reconstituted human NLRP1 could be activated following an artificial cleavage on the linker sequence 
even with its PYD replaced with a green fluorescent protein [51]. Therefore, it is hypothesized that the N-terminal 
region of NLRP1 plays an auto-inhibitory role instead of inflammasome signal transduction. It is interesting to 
note that mouse Nlrp1 lacks a PYD which suggests the possibility that PYD is capable of participating in an 
independent process to supplement NLRP1-mediated inflammation in the human system.  
Two known mechanisms of activation have been described for mouse Nlrp1b; N-terminal cleavage by 
anthrax LF and dipeptidyl peptidases 8 and 9 (DPP8 and DPP9) inhibition [52,53]. In murine macrophages, 
Nlrp1b is directly cleaved by anthrax LF at 44 amino acids from the N-terminus. Remarkably, it is the Nlrp1b 
molecule itself acts as a substrate for direct cleavage by anthrax LF, a process that is suggested to enable Nlrp1b 
to protect protection from anthrax toxicity by functioning as a decoy substrate that prevents LF from attacking 
MAPK kinases which are vital for host immunity. The cleavage of Nlrp1b generates a neo N-terminal which is 
targeted by ubiquitin and subsequently undergoes a proteasome-mediated proteolytic degradation known as the 
N-end rule pathway, which then liberates an active C-terminal fragment with potent inflammatory capacity, 
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consisting of the UPA-like domain attached to the CARD [54,55]. Presumably, it is for this reason that FIIND 
cleavage is crucial for the C-terminal UPA-CARD fragment to escape this degradation process. It is surprising, 
however, that studies in reconstituted human NLRP1 suggested that full-length protein degradation is not 
necessary for its activation, although FIIND autoproteolysis and N-terminal cleavage is [44,51]. This is interesting 
because the NOD in human NLRP1 contains Walker-A and Walker-B, two adenosine triphosphate (ATP)-binding 
motifs which are required for self-oligomerization and inflammasome assembly [56]. To our best knowledge, it 
is only the human NLRP1 that has been explicitly demonstrated to form inflammasome complex, thus raising the 
question of whether murine Nlrp1 is also capable of full inflammasome formation [37]. We propose that, unlike 
human NLRP1, it is possible that mouse Nlrp1b forms small complexes that recruits caspase-1 via CARD-CARD 
interaction without necessarily scaffolding into a complete inflammasome (Fig. 3). 
A more recently-uncovered mechanism of NLRP1 activation involves the inhibition of DPP8 and DPP9. 
These are intercellular serine peptidases that perform enzymatic non-reversible N-terminal cleavage on their 
peptide substrates. Members of the DPP family, especially DPP8 and DPP9, have been extensively studied for 
their importance in regulating a variety of biologically processes, the most important of which is in the immune 
system. Multiple studies have found that DPP8 and DPP9 inhibition elicits a host of anti-tumour immune 
responses including T cell activity and caspase-1-dependent pyroptosis in both immune cells and cancer cells [57–
59]. This has led to the development of several small-molecule DPP inhibitors such as Val-boroPro as potential 
cancer therapeutics. 
Two independent groups (Okondo et al. and de Vasconcelos et al.) have demonstrated that DPP8 and DPP9 
inhibition stimulates the activation of Nlrp1b inflammasome and caspase-1 [53,60]. In mouse macrophages with 
DPP8 and DPP9 inhibited with Val-boroPro, pyroptosis, and concomitantly caspase-1 maturation, ASC speck 
assembly, and secretion of mature IL-1β and IL-18, are significantly accelerated when challenged with anthrax 
LF, suggesting that DPP8 and DPP9 inhibition unleashes Nlrp1b for maximum inflammatory potency [60]. Nlrp1b 
activation by Dpp8 and Dpp9 inhibition is also characterised by N-terminal cleavage and degradation, albeit not 
via the N-end rule pathway but instead an indirect stimulation of endogenous proteasomal lysis pathway [55]. 
These results suggest that DPP8 and DPP9 are important immune suppressor molecules that serve as regulatory 
checkpoints upstream of inflammasome activity. As demonstrated by Zhong et al. in the human system, DPP9 in 
particular was shown to bind to NLRP1 FIIND and subsequently processes a currently unidentified protein with 
inflammasome repressive abilities [61]. Both NLRP1 FIIND binding and DPP9’s enzymatic function is necessary 
to restrict NLRP1 activity and identifying DPP9’s ligands may provide insightful information on inflammasome-
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mediated cellular inflammation and may prove to be useful in the development of novel anti-inflammatory 
compounds. FIIND binding by DPPs also reveals novel intramolecular regulatory mechanisms in inflammasomes 
as DPP8 and DPP9 inhibition also activate CARD8 which, like NLRP1, contains a FIIND directly upstream of a 
C-terminal CARD that undergoes auto-proteolysis as a sine qua non for its activation [43]. 
In the human system, NLRP1 activation initiates a structural conformational shift allows it oligomerization 
into the characteristic filamentous star-shaped conformation via clustering among NODs, followed by subsequent 
ASC speck formation and pro-caspase 1 recruitment to form the complete inflammasome complex (Fig. 4). The 
mechanisms of inflammasome assembly are reviewed in: [62,63]. In most other inflammasomes, the N-terminal 
PYD interacts with ASC via homotypic PYD-PYD attraction, which in turn recruit pro-caspase-1 (caspase-1 
zymogen) via interaction between the CARD of ASC and the CARD of pro-caspase-1.  As NLRP1 possesses its 
own CARD, it could theoretically bypass the requirement for ASC in caspase-1 recruitment. Indeed, it was 
observed that ASC-knockout mouse macrophages are able to produce Nlrp1b-mediated IL-1β and pyroptosis in 
response to anthrax LF without the occurrence of ASC-mediated speck formation and caspase-1 auto-proteolysis 
[64]. However, ASC speck formation could amplify inflammasome signalling by activating sufficient levels of 
caspase-1 for optimum downstream reactions including production of matured cytokines [65]. It is also 
noteworthy that in other inflammasomes, the signal transduction domain is located on the N-terminal upstream of 
NOD. Upon oligomerization, these inflammasomes orientate its PYD or CARD at the core of the complex to 
create a platform for ASC aggregation and caspase-1 activation. Since the CARD of NLRP1 is located at the C-
terminal, the pattern of oligomerization of NLRP1 could differ compared to other inflammasomes. The precise 
structural mechanism of NLRP1 inflammasome oligomerization is currently undetermined. 
 
Aβ activates NLRP1 inflammasome via P2X7 purinoceptor/pannexin 1 signalling 
Aβ is the product of alternative sequential cleavage of the amyloid precursor protein (APP) by β-secretase 
(BACE1) followed by γ-secretase. The popular but controversial amyloid cascade hypothesis (ACH) posits that 
the heavy production and deposition of Aβ peptides aggregates into insoluble fibrils which forms the major 
component of neuritic plaques which drive the neurodegenerative process [66]. Scientists have also discovered 
that the more soluble oligomeric form of Aβ is potentially more toxic to the brain compared to its fibril counterpart 
[67]. Aβ oligomers and fibrils are known inducers of neuroinflammation, owing to their ability to potentiate 
inflammasome activation [26]. A study by Tan et al. provided preliminary evidences that Aβ produced in the 
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brains of AD transgenic mice with mutant APP and presenilin 1 genes (APPswe/PS1dE9) indeed activates the 
Nlrp1 inflammasome leading to neuronal loss, likely through pyroptosis [36]. These transgenic mice exhibit 
cognitive and memory deficits compared to wild type mice. Moreover, Nlrp1-mediated pyroptosis-like death is 
also observed in in vitro cultured rat primary neurons challenged with Aβ oligomers. As NLRP1 is primarily 
expressed in pyramidal neurons and oligodendrocytes (both important cell types that make up the cerebral cortex, 
the hippocampus, and the amygdala), Aβ-induced NLRP1-mediated pyroptosis could result in destruction of such 
integral regions of the brain, leading to brain shrinkage and loss of vital cognitive functions and memory typically 
observed in AD patients [68]. Importantly, in vivo silencing of Nlrp1 and caspase-1 is able to rescue neurons from 
programmed cell death and markedly restored spatial learning in APPswe/PS1dE9 mice [36], alluding to the 
indispensable role of Nlrp1 and caspase-1 in AD neurodegeneration. However, the precise mechanism by which 
A activates the NLRP1 inflammasome remained to be elucidated. 
A series of studies by Orellana et al. proposed that Aβ-induced neuronal death in AD brains involves 
P2X7/pannexin 1 interaction [69,70]. Aβ oligomers are reported to induce ATP leakage in cells and at the same 
time, cause an overexpression of P2X7 purinergic receptors in both microglia and hippocampal neurons [70,71]. 
P2X7 receptors are ATP-gated cation channel which when stimulated by high concentrations of extracellular ATP 
(a DAMP typically released in high concentration to the extracellular matrix by injured or inflammatory cells), 
activates a non-selective ionic passage, including potassium (K+) ion efflux and calcium (Ca2+) influx. 
Additionally, P2X7 receptors co-activate with pannexin 1, a membrane hemichannel which creates pores allowing 
for the passage of much larger molecules, most notably ATP and IL-1β [72]. The pannexin 1 channel is activated 
by high concentration of extracellular K+ ions which effectively establishes a positive feedback activation 
mechanism with P2X7. More importantly, while the outcome of these findings by Orellana et al. demonstrated 
Aβ-induced neuronal death by synaptotoxicity distinct from inflammatory pathways, the K+/Ca2+ imbalance 
brought about by P2X7/pannexin 1 signalling is also a potent activator of inflammasomes, including NLRP1 
inflammasome in neurons (Fig. 4) [73,74]. P2X7/pannexin 1 activation by raised extracellular ATP has been 
shown to stimulate inflammasome activation through the adenosine monophosphate-activated protein kinase 
(AMPK) signalling pathway, which is hypothesized to further regulate membrane pore formation by P2X7 
receptors [75]. In a separate study on macrophages under hypoxic conditions, a reduced cytosolic ATP content 
(in addition to high extracellular ATP content) also activates the Nlrp1b inflammasome via AMPK-mediated 
pathway [76]. In both cases, inflammasome activities are evident in caspase-1 activation and the resultant IL-1β 
production and cellular pyroptosis. 
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Implications of NLRP1-mediated caspase-1 activation in AD 
Upon NLRP1 inflammasome activation, the recruited pro-caspase-1 cleaves into its P10 and P20 subunits 
which constitute the active enzyme. This initiates a cascade of downstream inflammatory signalling processes 
such as IL-1β and IL-18 maturation, caspase-6 activation and neuronal death leading to AD (Fig. 1) [77]. Caspases 
are a family of cysteine protease enzyme responsible for regulating physiological programmed cell death. There 
are three categories of caspases: apoptosis initiators (e.g. caspase-8 and caspase-9), apoptosis executioners (e.g. 
caspase-3, caspase-6 and caspase-7) and inflammatory caspases (e.g. caspase-1, caspase-4 and caspase-5) [78]. 
 
IL-1β and IL-18 maturation 
One of the principal functions of caspase-1 is to process IL-1β and IL-18 to maturity from their respective 
precursors, pro-IL-1 and pro-IL-18. Both IL-1β and IL-18 belongs to the IL-1 family which, although usually 
recognized as potent pro-inflammatory cytokines, are in fact constitutively expressed in controlled levels in the 
CNS and are essential for physiological neuromodulation [79]. IL-1β is excessively produced by microglia, 
astrocytes and neurons in response to brain injury. The intracellular signalling pathways elicited by IL-1β within 
the CNS are cell type-specific [80]. In glial cells, IL-1β regulates the production and release of inflammatory 
cytokines (IL-1, IL-6, monocyte chemoattractant protein-1 (MCP-1), and TNFs) through the activation of nuclear 
factor κB (NF-κB). In hippocampal neurons, IL-1β controls synaptic function by activating the cAMP response 
element-binding protein (CREB), a transcription factor which plays an integral role in neuronal plasticity and 
memory formation, via activation of the p38 MAPK (mitogen-activated protein kinase) pathway but not the 
MAPK/ERK (extracellular signal-regulated kinases) pathway. Experimentally, however, these events do not 
persist as the phosphorylation of CREB declines after only 20 minutes. Interestingly, in a study by Soiampornkul 
et al., IL-1β could suppress CREB activation by interfering with neurotrophin 3-induced Ras/MAPK/ERK and 
P13-K/Akt signalling pathways even at a concentration where neuron viability is not compromised [81]. CREB 
suppression might affect neuronal functionality by interfering with long-term potentiation which affects synaptic 
plasticity, memory formation and spatial awareness, possibly contributing to symptoms of dementia at early stages 
of AD including mild cognitive impairment (MCI) [82]. Indeed, a controlled level of IL-1β is essential for 
physiological regulation of neuronal functions and is even shown to be neuroprotective, as IL-1β was reported to 
decrease Aβ production and ameliorate amyloid burden, possibly through amplification of microglial-mediated 
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amyloid clearance or encouraging non-amyloidogenic processing of APP [83,84]. Despite reduced amyloid 
burden, overexpression of IL-1β instead encourages tau hyperphosphorylation mediated by p38 MAPK and 
glycogen synthase kinase 3 β (GSK-3β) signalling pathways [85]. At the same time, IL-1β mediates neuronal-
glial interaction which elevates neuronal acetylcholinesterase expression and activity which, in hippocampal 
neurons, is shown to impair excitatory synapses via disruption of neuroligin–neurexin junction which 
consequentially suppresses synaptic glutaminergic signalling [86,87]. 
Like IL-1β, IL-18 is another essential IL-1 cytokine which is expressed in healthy brain. Physiologically, 
IL-18 is shown to promote neuronal survivability by increasing the levels of brain-derived neurotrophic factor 
and the anti-apoptotic protein B-cell lymphoma 2 (BCL-2), whilst also inducing the expression of CREB. These 
processes sufficiently confer neuroprotection when cortical neurons are challenged with oxygen glucose-
deprivation [88]. However, IL-18 in AD patients is likewise abnormally upregulated in neurons and glial cells, 
especially at the frontal lobe where most of the dopamine neurons in the cerebral cortex are located [89]. Unlike 
IL-1β, increased levels of IL-18 is found to colocalize with both Aβ aggregations and hyperphosphorylated tau. 
In a study using SH-SY5Y human neuronal model, IL-18 is shown to promote Aβ production and aggregation by 
upregulating BACE1 and the N-terminal fragment of presenilin 1  [90]. At the same time, IL-18 upregulates kinase 
activities important for tau phosphorylation, including cyclin-dependent kinase 5 (Cdk5) and GSK-3β [91]. The 
actual impact of IL-18 in AD susceptibility is currently a subject of debate as multiple case-control studies on two 
functional polymorphisms in the IL-18 promoter gene (-607 C/A and -137 G/C) have reported conflicting results 
[92,93]. In the hopes of consolidating these findings, a meta-analysis conducted by Luo et al. revealed that such 
polymorphisms indeed decrease the risk of AD, particularly in Asian and apolipoprotein-ε4-positive (a significant 
AD risk gene) population [94]. However, these studies suffer from various limitations such as publication bias 
and small sample sizes. As with the NLRP1 gene, the genetic component of IL-18 in AD is not reflected in the 
most recent GWA study [35]. As such, larger scale studies on AD patient cytokine profiling may be required to 
re-evaluate the potential risks that IL-18 confers in AD. 
 
Pyroptosis 
Along with cytokine maturation, caspase-1 activation promotes an inflammatory programmed cell death 
known as pyroptosis, a caspase-1-dependent cell death characterized by host-mediated poration of the cell 
membrane which dissipates the cellular ionic gradient, producing a net increase of osmotic pressure, and cell 
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swelling [95]. As opposed to apoptosis, pyroptosis is characterized by membrane rupture causing the release of 
cytosolic contents, including DAMPs and pro-inflammatory cytokines such as ATP, IL-1 and IL-18 into the 
extracellular spaces to further perpetuate inflammatory responses. Recent evidence suggests that caspase-1 
induces pyroptosis via cleavage of the executioner protein gasdermin D, which  is a required component in 
inflammasome-mediated pyroptosis although it does not participate in IL-1β maturation [96]. Gasdermin D-
mediated pyroptosis, however, is required for IL-1β secretion to the extracellular spaces. The activation of 
gasdermin D is also dependent on its cleavage by caspase-1 on the linker between its N-terminal and C-terminal 
domains, where the N-terminus of gasdermin D is the effector of pyroptosis and the C-terminus functions as an 
intramolecular inhibitor when connected to the N-terminus [97]. Pyroptosis is typically observed in macrophages 
as a result of NLRP3 inflammasome activation. Macrophagic pyroptosis may be beneficial to the host as the 
released PAMPs are further cleared by surrounding neutrophils [98]. However, pyroptosis in brain cells can be 
particularly detrimental because it leads to permanent loss of neurons. While Tan et al. have demonstrated in 
cultured rat cortical neurons that Aβ induces NLRP1-mediated neuronal death, the presumption that pyroptosis is 
involved is not sufficiently conclusive as the TUNEL assay that was performed did not rule out other forms of 
cell death such as apoptosis [36]. As such, there are currently no available data that directly associate Aβ and 
neuronal pyroptosis. It is also not known if gasdermin D is expressed in neurons. Where gasdermin D is not 
present, NLRP1 activation instead induces cellular apoptosis via caspase-1 cleavage of caspase-3 and caspase-7 
[99]. It would be interesting therefore, to test for the effect of Aβ on possible gasdermin D activation in neurons 
to study the extent of neuronal pyroptosis that may be involved in AD. 
 
Caspase-6 activation 
Caspase-1 activation in human primary CNS neurons has been demonstrated to activate caspase-6 in an 
NLRP1-dependent manner [11]. Caspase-6 is a caspase of the apoptosis effector class which is expressed 
ubiquitously in the brain, including the entorhinal cortex, hippocampus and the striatum [100]. The 
pathophysiological role of caspase-6 is relatively complex as its function is not limited to apoptosis and does not 
always induce cell death when activated. Physiologically, caspase-6 plays a vital role in axon pruning during 
development and have apparent neuroprotective effects against ALS [101]. However, caspase-6 is also highly 
implicated in neurodegenerative diseases including HD and AD [102]. 
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Caspase-6 activity can be observed in all developmental stages of AD from non-cognitive impaired 
individuals to cases of very severe AD [103]. The abundance of caspase-6 activity in the entorhinal cortex and 
hippocampus also correlates inversely with episodic memory assessments, including in non-demented individuals, 
and is a reliable predictor of a person’s risk of developing AD [104]. Caspase-6 processes a range of substrates 
associated with neurodegenerative diseases including tau, APP, huntingtin and the presenilins 1 and 2 [105–108]. 
The presence of active caspase-6 in AD lesions including neuropil threads, neuritic plaques, and neurofibrillary 
tangles suggests caspase-6 is heavily involved in the production these pathologies [109]. In fact, caspase-6 is 
known to facilitate a number of events in early stages of AD which precede A and NFT formation. For example, 
caspase-6 functions synergistically with caspase-3 in tau Asp421 cleavage when stimulated by excessive reactive 
oxygen species, a sign of mitochondrial dysfunction [110,111]. Additionally, tau is further cleaved on the N-
terminal Asp13 by caspase-6, resulting in a compromised cytoskeletal stability that facilitates the formation of tau 
filament which could be phosphorylated by GSK-3β to produce NFTs [105]. Caspase-6 also encourages 
amyloidosis through cleavage of APP in a pathway distinct from that described in the ACH. As APP contains 
multiple caspase cleavage sites which are targeted by apoptotic caspases-3,-6,-7 and -8 independent of secretases, 
caspase-6 is shown to cleave APP at the C terminus, generating a 6.5 kDa fragment which could undergo further 
processing to produce Aβ peptides [106,112,113]. 
Caspase-6 activity may directly compromise neurons independent of Aβ and NFTs, possibly through 
aberrant apoptosis and axonal degeneration. In a study by LeBlanc et al., transgenic mice free from neuritic 
plaques and NFTs, but expressing an artificial self-activating form of human caspase-6 in the pyramidal neuron-
dense CA1 subfield of the hippocampus, were observed to develop neurodegeneration and memory impairments 
in an age-dependent manner [114]. As such, the removal of AD pathologies alone without eliminating caspase-6 
may be insufficient to halt AD progression. This presents the NLRP1 inflammasome in neurons as an attractive 
therapeutic target as both caspase-1-mediated neuroinflammation and caspase-6 activity may be simultaneously 
disrupted by eliminating the major platform from which they function. 
 
Conclusion and future perspectives 
The NLRP3 inflammasome in microglia, the resident macrophage of the CNS, have been well-
established as a potent driver neuroinflammation in AD. Here, we proposed that the NLRP1 inflammasome 
activity in neurons is equally paramount in the grand scheme of neuroinflammation in AD. Its capability to support 
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a myriad of inflammatory and neurodegenerative pathways within neurons themselves makes NLRP1 a potential 
therapeutic target for AD intervention. Recently, a study by Yin et al. has successfully demonstrated that JC-124, 
an NLRP3 inhibitor is able to decrease Aβ deposition and reduce microglia activation in an AD mouse model 
[115]. This is promising news as several studies have previously identified potential NLRP1 inhibitors that 
functions by preventing ATP-binding and inflammasome complex formation [116], although these are yet to be 
tested in AD conditions. These inhibitors may someday be developed into a new class of anti-neuroinflammatory 
drugs that can be used in combination with Aβ or NFT-targeting therapies to rescue neurons and hopefully modify 
disease progression in AD patients. However, there remain many challenges to be solved before such drugs may 
be developed as our current knowledge in inflammasome biology, particularly in the context of AD and other 
neurodegenerative diseases, are still in its adolescence. Given the complexity of the NLRP1 inflammasome and  
the extreme dissimilarity between its human and mice orthologues, we encourage future studies on neuronal 
NLRP1 to take advantage of recently-developed models derived from human induced pluripotent stem cells 
(iPSCs) which would undoubtedly represent the human conditions more accurately and at the same time facilitate 
drug discovery [117–119]. Neuroinflammation of the brain is increasingly recognized as a fundamental propagator 
of neurodegeneration in AD. By understanding precisely how inflammasomes work in the CNS under both 
physiological and pathological conditions, as well as figuring out how these inflammasomes can be targeted, we 
are one major step closer towards developing a proper cure for AD. 
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Figure captions 
Fig. 1 The activation of NLRP1 inflammasome by AD pathology, most notably Aβ, which ignites a cascade of 
reactions leading to loss of synapse and functional neurons. As NLRP1 is highly expressed in pyramidal neurons, 
the cerebral cortex, hippocampus and amygdala are most severely affected, thus leading to manifestation of the 
clinical symptoms of AD 
Fig. 2 Structures of NLRs that form inflammasomes. Human NLRP1 is structurally distinct from mice Nlrp1 
which contains 3 paralogues and lacks PYD. NLRP1 (with the exception of mouse Nlrp1C) contains a unique 
function-to-find domain (FIIND) and a functional CARD on its C-terminus 
Fig. 3 The activation model of mouse Nlrp1b which is characterised by ubiquitin-proteasome degradation post-
N-terminal cleavage, liberating an immunoactive C-terminal UPA-CARD fragment. As a consequent of this 
degradation, mouse Nlrp1b is not capable of forming a complete inflammasome complex. Instead, Nlrp1b relies 
on CARD-CARD interaction for inflammasome-like signalling with the support of ASC 
Fig. 4 NLRP1 can be activated by P2X7/pannexin 1 signalling under the influence of Aβ, prompting assembly of 
inflammasome. The expressions of NLRP1, pro-IL-1β and pro-IL-18 are driven by NF-κB signalling pathways. 
A region of the FIIND is post-translationally auto-cleaved as a requirement for its subsequent activation. NLRP1 
PYD might play an auto-inhibitory role which, when cleaved, activates the receptor to allow inflammasome 
complex formation. ASC are required to amplify caspase-1 recruitment for optimum downstream inflammasome 
activities including IL-1β and IL-18 maturation 
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